Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CES2 | O00748 | 3/20 | 0.48 |
| ▸ | CES1 | P23141 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9152657 | 0.94 | MLYCD (0.53) | MLYCDTDP1ALDH1A1LMNACES2 | |
| SCHEMBL9707103 | 0.91 | MLYCD (0.54) | MLYCDTDP1ALDH1A1LMNACES2 | |
| SCHEMBL1012521 | 0.83 | MLYCD (0.57) | MLYCDALDH1A1LMNASMN1; SMN2HSD17B1 | |
| SCHEMBL22531823 | 0.83 | MLYCD (0.57) | MLYCDALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL1303906 | 0.83 | MLYCD (0.57) | MLYCDTDP1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3305455 | 0.82 | ALDH1A1 (0.57) | MLYCDTDP1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6616024 | 0.82 | MLYCD (0.56) | MLYCDTDP1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL286256 | 0.82 | CES2 (0.57) | MLYCDALDH1A1CES2CES1SMN1; SMN2 | |
| SCHEMBL306600 | 0.82 | MLYCD (0.60) | MLYCDALDH1A1CES2CES1SMN1; SMN2 | |
| SCHEMBL623946 | 0.82 | PKM (0.56) | MLYCDTDP1ALDH1A1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-31 | — | — | US | disclosed |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-11279713-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-22 | — | — | US | disclosed |
| EP-3822253-A1 | METHOD FOR PREPARING PROPANEDINITRILE OXIME ETHER COMPOUND AND INTERMEDIATE COMPOUND | Shenyang Sinochem Agrochemicals R&D Co., Ltd. (CN) | 2021-05-19 | — | — | EP | disclosed |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-08 | — | — | US | disclosed |
| EP-3302486-B1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-3302486-B1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-09-30 | — | — | EP | disclosed |
| US-10654874-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-19 | — | — | US | disclosed |
| EP-2603513-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF AS AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-10544092-B2 | Malononitrile oxime ether compound and use thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2020-01-28 | — | — | US | disclosed |
| US-7205302-B2 | Anticoagulants; antilipemic agents; cardiovascular disorders | NIPPON SHINYAKU CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| EP-1400518-B1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | NIPPON SHINYAKU CO LTD (JP) | 2007-01-17 | — | — | EP | disclosed |
| EP-1737840-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-01-03 | — | — | EP | disclosed |
| US-7157580-B2 | Aminopyrimidine and aminopyridine anti-inflammation agents | ROCHE PALO ALTO LLC (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157580-B2 | Aminopyrimidine and aminopyridine anti-inflammation agents | ROCHE PALO ALTO LLC (US) | 2007-01-02 | — | — | US | disclosed |
| WO-2005103033-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2005-11-03 | — | — | WO | disclosed |
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | NIPPON SHINYAKU CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1400518-A1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | Nippon Shinyaku Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-5494918-A | ANTICHOLESTEROL AGENTS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-02-27 | — | — | US | disclosed |
| US-5385912-A | Hypocholesterolemic or hypolipidemic agents | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544092-B2 | Malononitrile oxime ether compound and use thereof | ME1, MAL2, ME3 | MLYCD 28/4885TDP1 2969/4885ALDH1A1 791/4885 |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | MLYCD 2341/4885TDP1 813/4885ALDH1A1 177/4885 |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | MLYCD 2341/4885TDP1 813/4885ALDH1A1 177/4885 |
| US-10654874-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2C, GRIN2A | MLYCD 2341/4885TDP1 813/4885ALDH1A1 177/4885 |
| US-11279713-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2C, GRIN2A | MLYCD 2341/4885TDP1 813/4885ALDH1A1 177/4885 |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | MLYCD 3640/4885TDP1 3959/4885ALDH1A1 132/4885 |
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | CNR2, CNR1, GPR55 | MLYCD 3426/4885TDP1 4708/4885ALDH1A1 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.